Go Pro
→ The only metrics you should watch as a day trader. (From The TradingPub) (Ad)tc pixel
NASDAQ:IBIO

iBio Q1 2026 Earnings Report

iBio logo
$1.44 -0.01 (-0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$1.46 +0.02 (+1.04%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

iBio EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

iBio Revenue Results

Actual Revenue
$0.10 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Announcement Details

Quarter
Q1 2026
Date
11/12/2025
Time
After Market Closes
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

iBio's Q4 2026 earnings is estimated for Friday, September 4, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

iBio's Q1 2026 Earnings ReleaseEarnings Release
(8-K)
iBio's Q1 2026 Quarterly ReportQuarterly Report
(10-Q)

iBio Earnings Headlines

iBio (NASDAQ:IBIO) Rating Increased to Hold at Wall Street Zen
July 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30877602
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO)
July 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IBIO/pressreleases/3111524/analysts-offer-insights-on-healthcare-companies-candel-therapeutics-cadl-and-ibio-ibio/
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI breakthrough they call 'M.A.G.I.' will collide with a rare market pattern by July 30. That pattern carries a 100% historical track record. The last time it triggered, early investors had a chance to turn $10,000 into as much as $350,000 in roughly 12 months.tc pixel
July 14 at 1:00 AM  |  Brownstone Research (Ad)
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
July 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320497/0/en/ibio-reports-single-dose-of-ibio-610-achieved-near-complete-active-activin-e-inhibition-through-eight-weeks-in-obese-nhp-study.html
Could iBio (IBIO) Be an Underrated Obesity Stock?
June 11, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/could-ibio-ibio-be-an-underrated-obesity-stock-1780088/
5 Under-the-Radar AI Stocks to Buy in 2026
June 11, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/5-under-the-radar-ai-stocks-to-buy-in-2026-1778220/
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NASDAQ:IBIO), a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

View iBio Profile
Earnings Tools